<i>In Vitro</i>
            Activity of Ozenoxacin against Quinolone-Susceptible and Quinolone-Resistant Gram-Positive Bacteria

López, Yuly; Tato, Marta; Espinal, Paula; García-Alonso, Fernando; Gargallo-Viola, Domingo; Cantón, Rafael; Vila, Jordi

doi:10.1128/aac.01509-13

Cited by 40 publications

(37 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These findings are in agreement with previous reports indicating that the antimicrobial activity of ozenoxacin is more potent than that of the existing quinolone antimicrobial agents, including nadifloxacin, against clinical isolates of P. acnes and Staphylococcus spp. (Yakamawa et al, 2002;López et al, 2013López et al, , 2015. In our study, we selected nadifloxacin as a reference quinolone because it has been widely used for topical application of acne vulgaris in Japan.…”

Section: Discussionmentioning

confidence: 99%

“…In Japan, 2 % ozenoxacin-containing lotion (Zebiax® Lotion 2 %; Maruho, Osaka, Japan) has recently been approved as an ethical pharmaceutical agent for acne vulgaris and superficial skin infections such as folliculitis, sycosis, periporitis suppurativa and impetigo (Kawashima et al, 2015a, b). Ozenoxacin has a broad antimicrobial spectrum against both Grampositive and Gram-negative organisms, including major pathogenic bacteria of acne vulgaris and superficial skin infections such as P. acnes, Staphylococcus aureus and Staphylococcus epidermidis (Yamakawa et al, 2002;López et al, 2013López et al, , 2015Tato et al, 2014). Moreover, ozenoxacin was the most potent against all organisms compared to any reference antimicrobial agents tested (Yamakawa et al, 2002;López et al, 2013López et al, , 2015Tato et al, 2014).…”

Section: Introductionmentioning

confidence: 94%

“…Ozenoxacin has a broad antimicrobial spectrum against both Grampositive and Gram-negative organisms, including major pathogenic bacteria of acne vulgaris and superficial skin infections such as P. acnes, Staphylococcus aureus and Staphylococcus epidermidis (Yamakawa et al, 2002;López et al, 2013López et al, , 2015Tato et al, 2014). Moreover, ozenoxacin was the most potent against all organisms compared to any reference antimicrobial agents tested (Yamakawa et al, 2002;López et al, 2013López et al, , 2015Tato et al, 2014). However, to date there are no data concerning the in vitro antimicrobial activity of ozenoxacin against bacteria isolated from patients with acne vulgaris.…”

Section: Introductionmentioning

confidence: 96%

“…Ozenoxacin is a novel des-fluoro-(6)-quinolone antimicrobial agent developed for topical use (Yamakawa et al, 2002;López et al, 2013). In Japan, 2 % ozenoxacin-containing lotion (Zebiax® Lotion 2 %; Maruho, Osaka, Japan) has recently been approved as an ethical pharmaceutical agent for acne vulgaris and superficial skin infections such as folliculitis, sycosis, periporitis suppurativa and impetigo (Kawashima et al, 2015a, b).…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Antimicrobial activities of ozenoxacin against isolates of propionibacteria and staphylococci from Japanese patients with acne vulgaris

Nakajima

Ikeda

Kanayama

et al. 2016

Journal of Medical Microbiology

View full text Add to dashboard Cite

Ozenoxacin, a novel non-fluorinated topical quinolone, was assessed for in vitro antimicrobial activity against clinical isolates of propionibacteria and staphylococci according to the broth microdilution method recommended by the Clinical and Laboratory Standards Institute. The isolates used in this study were collected from Japanese patients with acne vulgaris during a period from 2012 to 2013. The MIC 90 s of ozenoxacin against Propionibacterium acnes (n=266), Propionibacterium granulosum (n=10), Staphylococcus aureus (n=23), Staphylococcus epidermidis (n=229) and other coagulase-negative staphylococci (n=82) were 0.06, 0.06, 0.06, 0.125 and 0.06 µg ml À1 , respectively. The antimicrobial activity of ozenoxacin against the clinical isolates of propionibacteria and staphylococci was greater than that of five reference antimicrobial agents which have been used for the treatment of acne vulgaris. The MICs of ozenoxacin were correlated with those of nadifloxacin in P. acnes and S. epidermidis isolates. However, the MICs of ozenoxacin were 0.25-0.5 µg ml À1 and 0.5-8 µg ml À1 against nadifloxacin-resistant P. acnes (MIC: !8 µg ml À1 ; n=8) and S. epidermidis (MIC: !64 µg ml À1 ; n=10), respectively. These results indicated the potent antimicrobial activity against P. acnes and S. epidermidis isolates resistant to nadifloxacin. Topical ozenoxacin could represent an alternative therapeutic drug for acne vulgaris based on its potent antimicrobial activity against the isolates of propionibacteria and staphylococci from acne patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 94%

Section: Introductionmentioning

confidence: 96%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Antimicrobial activities of ozenoxacin against isolates of propionibacteria and staphylococci from Japanese patients with acne vulgaris

Nakajima

Ikeda

Kanayama

et al. 2016

Journal of Medical Microbiology

View full text Add to dashboard Cite

show abstract

“…Preclinical tests have shown that ozenoxacin possesses potent bacteriostatic and bactericidal activity against Gram-positive pathogens such as S. aureus and Streptococcus pyogenes, organisms that are frequently associated with skin and soft-tissue infections [6][7][8]. These studies indicated that a simplified once-or twice-daily treatment schedule was feasible and should be advantageous in terms of improving compliance and minimizing the risk of treatment failure and the development of resistant strains.…”

mentioning

confidence: 99%

Ozenoxacin: A Review of Absorption, Dermal Exposure and Toxicity, Tolerability and Safety Studies

Gropper¹

2014

Future Microbiol.

View full text Add to dashboard Cite

Efficacy and Safety of Ozenoxacin Cream for Treatment of Adult and Pediatric Patients With Impetigo

Rosen

Albareda

Rosenberg³

et al. 2018

JAMA Dermatol

View full text Add to dashboard Cite

IMPORTANCE Ozenoxacin, a novel topical antibacterial agent with potent bactericidal activity against gram-positive bacteria, has been developed as a cream with 1% active drug for the treatment of impetigo, a highly contagious bacterial skin infection. OBJECTIVES To evaluate the efficacy, safety, and tolerability of ozenoxacin cream, 1%, after 5-day twice-daily topical treatment in patients with impetigo. DESIGN, SETTING, AND PARTICIPANTS This randomized, double-blind, vehicle-controlled clinical trial included patients 2 months or older with impetigo who were enrolled at centers in 6 countries from June 2, 2014, through May 30, 2015. Data were analyzed based on intention to treat from July 9 through July 22, 2015. INTERVENTIONS Patients were randomized 1:1 to receive topical ozenoxacin or placebo control. MAIN OUTCOMES AND MEASURES Efficacy was measured using the Skin Infection Rating Scale and microbiological culture. Safety and tolerability were also evaluated. RESULTS Among the 411 patients who received treatment (210 males [51.1%]; mean [SD] age, 18.6 [18.3] years), ozenoxacin demonstrated superior clinical success compared with placebo, which was evident after 5 days of therapy (112 of 206 [54.4%] vs 78 of 206 [37.9%]; P = .001). Ozenoxacin also demonstrated superior microbiological success compared with placebo after 2 days of therapy (109 of 125 [87.2%] vs 76 of 119 [63.9%]; P = .002). Ozenoxacin was well tolerated, with 8 of 206 patients experiencing adverse effects, with only 1 of these potentially related to the study treatment; none were serious. CONCLUSIONS AND RELEVANCE Topical ozenoxacin is effective and well tolerated in the treatment of impetigo in patients 2 months and older. This effect is demonstrated by rapid onset of response and superior clinical and microbiological response compared with placebo. Topical ozenoxacin represents a novel option for the treatment of impetigo.

show abstract

In Vitro Activity of Ozenoxacin against Quinolone-Susceptible and Quinolone-Resistant Gram-Positive Bacteria

Cited by 40 publications

References 17 publications

Antimicrobial activities of ozenoxacin against isolates of propionibacteria and staphylococci from Japanese patients with acne vulgaris

Antimicrobial activities of ozenoxacin against isolates of propionibacteria and staphylococci from Japanese patients with acne vulgaris

Ozenoxacin: A Review of Absorption, Dermal Exposure and Toxicity, Tolerability and Safety Studies

Efficacy and Safety of Ozenoxacin Cream for Treatment of Adult and Pediatric Patients With Impetigo

Contact Info

Product

Resources

About